Tag: Clinical Trial Phases clinical trial phases

Single-Arm vs. Parallel-Group Designs: When to Use Them

Posted on digi By digi

Single-Arm vs. Parallel-Group Designs: When to Use Them Choosing Between Single-Arm and Parallel-Group Designs in Phase 2 Trials Introduction In Phase 2 clinical trials, choosing the right study design is crucial to obtaining reliable and meaningful results. Two commonly used approaches are the single-arm design and the parallel-group design. Each has distinct advantages and limitations…

Read More “Single-Arm vs. Parallel-Group Designs: When to Use Them” »

Phase 2 (Efficacy and Side Effects)

Dose-Ranging and Dose-Finding Strategies in Phase 2

Posted on digi By digi

Dose-Ranging and Dose-Finding Strategies in Phase 2 How Dose-Ranging and Dose-Finding Strategies Shape Phase 2 Clinical Trials Introduction One of the most important objectives in a Phase 2 clinical trial is to identify the optimal dose of an investigational drug. This is done through well-structured dose-ranging and dose-finding studies that evaluate different dosage levels for…

Read More “Dose-Ranging and Dose-Finding Strategies in Phase 2” »

Phase 2 (Efficacy and Side Effects)

Sentinel Dosing in First-in-Human Studies: Why and How It’s Done

Posted on digi By digi

Sentinel Dosing in First-in-Human Studies: Why and How It’s Done Sentinel Dosing in First-in-Human Studies: Why and How It’s Done Introduction Sentinel dosing is a critical risk mitigation strategy in first-in-human (FIH) clinical trials. It involves administering the investigational product (IP) to one or two participants before exposing additional volunteers to the same dose. This…

Read More “Sentinel Dosing in First-in-Human Studies: Why and How It’s Done” »

Phase 1 (Safety and Dosage)

Adaptive Designs in Phase 2: Interim Analyses and Seamless Designs

Posted on digi By digi

Adaptive Designs in Phase 2: Interim Analyses and Seamless Designs Understanding Adaptive Designs in Phase 2 Trials: Interim Analyses and Seamless Strategies Introduction As clinical development becomes more resource-intensive, there is a growing need for flexible and efficient trial methodologies. Adaptive designs in Phase 2 clinical trials offer the ability to make pre-specified modifications to…

Read More “Adaptive Designs in Phase 2: Interim Analyses and Seamless Designs” »

Phase 2 (Efficacy and Side Effects)

Dose Escalation Designs in Phase 1: 3+3, BOIN, mTPI, CRM Explained

Posted on digi By digi

Dose Escalation Designs in Phase 1: 3+3, BOIN, mTPI, CRM Explained Dose Escalation Designs in Phase 1 Trials: 3+3, BOIN, mTPI, and CRM Explained Introduction In Phase 1 clinical trials, dose escalation is a critical step in determining the maximum tolerated dose (MTD) or identifying a biologically effective dose. The design you choose directly influences…

Read More “Dose Escalation Designs in Phase 1: 3+3, BOIN, mTPI, CRM Explained” »

Phase 1 (Safety and Dosage)

Randomized Controlled Phase 2 Trials: Pros and Cons

Posted on digi By digi

Randomized Controlled Phase 2 Trials: Pros and Cons Evaluating the Pros and Cons of Randomized Controlled Trials in Phase 2 Introduction Randomized controlled trials (RCTs) are often considered the gold standard in clinical research due to their ability to minimize bias and provide high-quality evidence. In Phase 2 clinical trials, where the goal is to…

Read More “Randomized Controlled Phase 2 Trials: Pros and Cons” »

Phase 2 (Efficacy and Side Effects)

Determining the Starting Dose for First-in-Human Trials (MABEL, NOAEL, BSA)

Posted on digi By digi

Determining the Starting Dose for First-in-Human Trials (MABEL, NOAEL, BSA) Determining the Starting Dose for First-in-Human Trials: MABEL, NOAEL, and BSA Explained Introduction In first-in-human (FIH) trials, selecting the initial dose is one of the most important and scrutinized decisions. Too high, and you risk harm to participants. Too low, and the data may be…

Read More “Determining the Starting Dose for First-in-Human Trials (MABEL, NOAEL, BSA)” »

Phase 1 (Safety and Dosage)

Common Study Designs in Phase 2 Trials

Posted on digi By digi

Common Study Designs in Phase 2 Trials Exploring Common Study Designs Used in Phase 2 Clinical Trials Introduction Phase 2 clinical trials are designed to evaluate whether a new therapeutic candidate is effective in a specific patient population. Since these trials follow the safety-focused Phase 1 stage, the emphasis shifts toward efficacy assessment, dose optimization,…

Read More “Common Study Designs in Phase 2 Trials” »

Phase 2 (Efficacy and Side Effects)

Site Selection and Infrastructure Needs for Early-Phase Trials

Posted on digi By digi

Site Selection and Infrastructure Needs for Early-Phase Trials Site Selection and Infrastructure Needs for Early-Phase Trials Introduction Early-phase clinical trials—especially Phase 1 studies—require specialized environments for participant safety, data integrity, and regulatory compliance. Choosing the right site is a critical success factor. From facility readiness to investigator experience, this tutorial explores how to select, prepare,…

Read More “Site Selection and Infrastructure Needs for Early-Phase Trials” »

Phase 1 (Safety and Dosage)

Transition Criteria from Phase 1 to Phase 2 Clinical Trials

Posted on digi By digi

Transition Criteria from Phase 1 to Phase 2 Clinical Trials How Drugs Move from Phase 1 to Phase 2: Transition Criteria and Developmental Milestones Introduction The transition from Phase 1 to Phase 2 is one of the most critical decision points in drug development. It marks the move from initial human safety testing to early…

Read More “Transition Criteria from Phase 1 to Phase 2 Clinical Trials” »

Phase 2 (Efficacy and Side Effects)